• Ceftaroline fosamil is the latest addition to the armamentarium for the treatment of patients with community-acquired pneumonia (CAP).

• In the phase III clinical trials, clinical success at the test of cure visit was 84.3% among patients that received ceftaroline versus patients who received ceftriaxone (difference 6.7%, 95% confidence interval (CI), 1.6% to 11.8%) in the clinically evaluable population.

• In a real-world cohort study (CAPTURE) ceftaroline demonstrated similar cure rates to those seen in clinical trials.

• Data from the CAPTURE registry evaluate the use of ceftaroline in special populations with CAP such as older adults, critically ill patients and those with MRSA pneumonia.

• As CAPTURE is a retrospective, non-comparator convenient sample registry, all findings need to be interpreted with extreme caution.

This summary slide represents the opinions of the authors. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).